CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022

UNITED THERAPEUTICS Corp

CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.
Coverage effective June 5, 2022, after a 45-day notice period as announced April 21, 2022.
Tyvaso is a treprostinil inhalation solution marketed by United Therapeutics for pulmonary hypertension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.